体重指数作为多形性胶质母细胞瘤预后标志物的临床结局研究
这项回顾性研究纳入392例组织病理学确诊的胶质母细胞瘤患者,分析治疗前体重指数(BMI)与总生存(OS)的关联。中位随访48.6个月,正常体重组中位OS为13.5个月,超重组为15.4个月,肥胖组为15.1个月;校正年龄、卡氏功能评分和切除范围后,超重和肥胖患者的死亡风险比分别为0.70和0.66。作者认为BMI升高与更好的OS相关,其机制需进一步探索。
要点
- 392例胶质母细胞瘤患者中,正常体重组中位OS为13.5个月,超重组为15.4个月,肥胖组为15.1个月。
- 校正年龄、卡氏功能评分和切除范围后,超重患者HR为0.70(95%CI 0.54-0.92;P=.009),肥胖患者HR为0.66(95%CI 0.45-0.98;P=.04)。
- 性别、糖尿病和高血压与BMI无显著交互作用,作者结论为BMI升高与更好的OS相关,机制需进一步探索。
核心结论
- 作者结论为在其系列患者中,BMI升高的胶质母细胞瘤患者总生存显著更好,该交互作用的机制需进一步探索以理解此关联。
研究设计与样本
- 回顾性研究,仅纳入组织病理学确诊的胶质母细胞瘤患者,共分析392例2008年1月至2016年6月治疗的患者数据。
- BMI由首次检查时记录的身高和体重计算,治疗均为同步放化疗联合替莫唑胺后替莫唑胺维持治疗。
- 主要终点为总生存,采用单因素和多因素Cox比例风险模型评估BMI作为连续变量和分类变量的死亡风险。
- BMI分类标准:18.5至24.9 kg/m2为正常,25.0至29.9 kg/m2为超重,≥30.0 kg/m2为肥胖。
主要发现
- 中位随访48.6个月,正常体重组中位OS为13.5个月,超重组为15.4个月,肥胖组为15.1个月。
- 共81%的患者死亡。
- 校正年龄、卡氏功能评分和切除范围后,超重患者HR为0.70(95%CI 0.54-0.92;P=.009),肥胖患者HR为0.66(95%CI 0.45-0.98;P=.04)。
- 性别、糖尿病和高血压与BMI无显著交互作用。
关键数值与推荐
- BMI分类标准:18.5至24.9 kg/m2为正常,25.0至29.9 kg/m2为超重,≥30.0 kg/m2为肥胖。
- 超重患者校正后HR为0.70(95%CI 0.54-0.92;P=.009),肥胖患者校正后HR为0.66(95%CI 0.45-0.98;P=.04)。
- 正常体重组中位OS为13.5个月,超重组为15.4个月,肥胖组为15.1个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Correlation of body mass index (BMI) with clinical outcome in patients with glioblastoma is not well documented. Hence, we studied the association between survival and pretreatment BMI in glioblastoma patients. METHODS AND MATERIALS: In this retrospective study, only patients with histopathology-confirmed glioblastoma were included. Their BMIs were calculated from height and weight measurements and recorded in medical records at their first examination. Treatment plans for all patients consisted of concurrent radiation therapy and temozolomide, followed by maintenance therapy with temozolomide. The primary endpoint was overall survival (OS). Univariate and multivariate Cox proportional hazards models were used to estimate the mortality risk associated with BMI as a continuous and categorical variable. A BMI of 18.5 to 24.9 kg/m2 was classified as normal, 25.0 to 29.9 kg/m2 as overweight, and ≥30.0 kg/m2 as obese. RESULTS: Data from 392 patients treated from January 2008 through June 2016 were analyzed. At a median follow-up of 48.6 months, the median OS was 13.5 months in normal subjects, 15.4 months in overweight subjects, and 15.1 months in obese subjects. A total of 81% of the patients died. The hazard ratios for overweight and obese patients were 0.70 (95% confidence interval, 0.54-0.92; P = .009) and 0.66 (95% confidence interval, 0.45-0.98; P = .04), respectively, when adjusted for age, Karnofsky performance score, and extent of resection. Sex, diabetes, and hypertension had no significant interactions. CONCLUSIONS: Patients with elevated BMIs had significantly better OS in our series of patients. The mechanism of this interaction needs to be explored further to understand this association.
引用
- Potharaju M, Mangaleswaran B, Mathavan A, et al. Body Mass Index as a Prognostic Marker in Glioblastoma Multiforme: A Clinical Outcome. Int J Radiat Oncol Biol Phys. 2018. PMID: 30102196. doi:10.1016/j.ijrobp.2018.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。